Macular retinal edema
Therapeutic area
Neurology
Rare disease
No
- Definition
- Accumulation of intraretinal fluid and protein in the macula, which may result in swelling and decreased central vision.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Macular retinal edema
- Therapeutic area
- Neurology
- macular retinal edema
- macula lutea retinal edema
- macula lutea retinal oedema
- macular edema
- retinal edema of macula lutea
- retinal oedema of macula lutea
- Severity
- Moderate
- Neurology
- Ophthalmology
- MONDO ID
- MONDO:0003005
- Parent condition
- MONDO:0003004
Related records
Broader conditions (11)
- Disease
- Disease by body system or component
- Disorder of orbital region
- Disorder of visual system
- Eye disorder
- Human disease
- Macular degeneration
- Nervous system disorder
- Retinal degeneration
- Retinal disorder
- Retinal edema
Narrower conditions (1)
- Cystoid macular edema
Trials (416)
- "Cataract Surgery in Eyes With Epiretinal Membrane"
- 20- Versus 23- Gauge System for Pars Plana Vitrectomy
- A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
- A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
- A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
- A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
- A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
- A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
- A Long-Term Safety Study of OZURDEX® in Clinical Practice
- A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
- A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
- A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema
- A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
- A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
- A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
- A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes
- A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
- A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO
Approved drugs (5)
- Aflibercept
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab
Drugs in development (18)
- Abicipar pegol Phase 2
- Acetazolamide Phase 2
- Betamethasone Phase 2
- Bevacizumab Phase 3
- Brolucizumab Phase 3
- Denufosol tetrasodium Phase 2
- Dexamethasone phosphoric acid Phase 1
- GSK2798745 Phase 1
- Interferon beta Phase 3
- Ketorolac tromethamine Phase 2
- Methotrexate Phase 3
- Nepafenac Phase 2
- Pegaptanib sodium Phase 3
- Prednisolone acetate Phase 2
- Triamcinolone Phase 3
- Triamcinolone acetonide Phase 3
- Trientine hydrochloride Phase 2
- Vamikibart Phase 3
Other linked drugs (1)
- Ketorolac